BIOMAT Database Logo BIOMAT Database Logo

Tumor necrosis factor and interferon-gamma augment anticolon antibody- dependent cellular cytotoxicity in ulcerative colitis. 1996

N Watanabe, and M Maeda, and T Okamoto, and H Sasaki, and N Tsuji, and S Akiyama, and D Kobayashi, and T Sato, and N Yamauchi, and Y Niitsu
Fourth Department of Internal Medicine, Sapporo Medical University School of Medicine, Japan.

The effect of tumor necrosis factor (TNF) and interferon (IFN)-gamma on antibody-dependent cellular cytotoxicity (ADCC) in patients with ulcerative colitis (UC) was investigated. ADCC activity was measured by the 51Cr release assay, using peripheral blood mononuclear cells of healthy subjects as effector cells and RPMI 4788 cells derived from human colon cancer as target cells. ADCC activity under sera from healty subjects remained low whether or not the effector cells were pretreated with TNF (100 U/ml, 16h). Under sera from UC patients, ADCC activity of 13.9%, compared to 9.6% when pretreatment was deleted. The effect of IFN pretreatment (100 U/ml, 16h) was also examined under sera from UC patients; in that experiment activity rose to 26.8%, in comparison to a 10.7% when IFN-gamma pretreatment was deleted. Finally, when the effector cells were pretreated with both TNF and IFN-gamma (100 U/ml of each, 16h) the ADCC activity under sera from UC patients was higher than when either TNF or IFN-gamma were used alone. These results suggest that TNF and IFN-gamma, by increasing ADCC activity in UC lesions, are involved in cell injury in the colonic epithelium. IFN-gamma appears to increase ADCC activity by increasing the number of high affinity monocyte Fc gamma RI receptors, while TNF increases ADCC activity by a different mechanism.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007963 Leukocytes, Mononuclear Mature LYMPHOCYTES and MONOCYTES transported by the blood to the body's extravascular space. They are morphologically distinguishable from mature granulocytic leukocytes by their large, non-lobed nuclei and lack of coarse, heavily stained cytoplasmic granules. Mononuclear Leukocyte,Mononuclear Leukocytes,PBMC Peripheral Blood Mononuclear Cells,Peripheral Blood Human Mononuclear Cells,Peripheral Blood Mononuclear Cell,Peripheral Blood Mononuclear Cells,Leukocyte, Mononuclear
D011961 Receptors, Fc Molecules found on the surface of some, but not all, B-lymphocytes, T-lymphocytes, and macrophages, which recognize and combine with the Fc (crystallizable) portion of immunoglobulin molecules. Fc Receptors,Fc Receptor,Receptor, Fc
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D003093 Colitis, Ulcerative Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN. Colitis Gravis,Idiopathic Proctocolitis,Inflammatory Bowel Disease, Ulcerative Colitis Type,Ulcerative Colitis
D004306 Dose-Response Relationship, Immunologic A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell. Immunologic Dose-Response Relationship,Relationship, Immunologic Dose-Response,Dose Response Relationship, Immunologic,Dose-Response Relationships, Immunologic,Immunologic Dose Response Relationship,Immunologic Dose-Response Relationships,Relationship, Immunologic Dose Response,Relationships, Immunologic Dose-Response
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000920 Antibody-Dependent Cell Cytotoxicity The phenomenon of antibody-mediated target cell destruction by non-sensitized effector cells. The identity of the target cell varies, but it must possess surface IMMUNOGLOBULIN G whose Fc portion is intact. The effector cell is a "killer" cell possessing Fc receptors. It may be a lymphocyte lacking conventional B- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent. ADCC,Cytotoxicity, Antibody-Dependent Cell,Cell Cytoxicity, Antibody-Dependent,Antibody Dependent Cell Cytotoxicity,Antibody-Dependent Cell Cytotoxicities,Antibody-Dependent Cell Cytoxicities,Antibody-Dependent Cell Cytoxicity,Cell Cytotoxicities, Antibody-Dependent,Cell Cytotoxicity, Antibody-Dependent,Cell Cytoxicities, Antibody-Dependent,Cell Cytoxicity, Antibody Dependent,Cytotoxicities, Antibody-Dependent Cell,Cytotoxicity, Antibody Dependent Cell,Cytoxicities, Antibody-Dependent Cell,Cytoxicity, Antibody-Dependent Cell

Related Publications

N Watanabe, and M Maeda, and T Okamoto, and H Sasaki, and N Tsuji, and S Akiyama, and D Kobayashi, and T Sato, and N Yamauchi, and Y Niitsu
Interleukin 2 and interferon-gamma augment anticolon antibody dependent cellular cytotoxicity in ulcerative colitis.
June 1993, Gut,
N Watanabe, and M Maeda, and T Okamoto, and H Sasaki, and N Tsuji, and S Akiyama, and D Kobayashi, and T Sato, and N Yamauchi, and Y Niitsu
Tumor necrosis factor and chemotherapeutic agents. Potentiation of cytotoxicity with interferon gamma.
November 1992, Archives of otolaryngology--head & neck surgery,
N Watanabe, and M Maeda, and T Okamoto, and H Sasaki, and N Tsuji, and S Akiyama, and D Kobayashi, and T Sato, and N Yamauchi, and Y Niitsu
Tumor necrosis factor and interferon-gamma down-regulate Klotho in mice with colitis.
April 2010, Gastroenterology,
N Watanabe, and M Maeda, and T Okamoto, and H Sasaki, and N Tsuji, and S Akiyama, and D Kobayashi, and T Sato, and N Yamauchi, and Y Niitsu
[Analysis of anticolon antibody and lymphocytophilic antibody in sera from patients with ulcerative colitis].
March 1985, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology,
N Watanabe, and M Maeda, and T Okamoto, and H Sasaki, and N Tsuji, and S Akiyama, and D Kobayashi, and T Sato, and N Yamauchi, and Y Niitsu
Interferon-gamma enhances expression of cellular receptors for tumor necrosis factor.
April 1986, Journal of immunology (Baltimore, Md. : 1950),
N Watanabe, and M Maeda, and T Okamoto, and H Sasaki, and N Tsuji, and S Akiyama, and D Kobayashi, and T Sato, and N Yamauchi, and Y Niitsu
Effects of Soluble Tumor Necrosis Factor (TNF) on Antibody-Dependent Cellular Cytotoxicity of Therapeutic anti-TNF-α Antibody.
July 2019, Immunological investigations,
N Watanabe, and M Maeda, and T Okamoto, and H Sasaki, and N Tsuji, and S Akiyama, and D Kobayashi, and T Sato, and N Yamauchi, and Y Niitsu
Anti-tumor necrosis factor therapy for ulcerative colitis.
September 2005, Gastroenterology,
N Watanabe, and M Maeda, and T Okamoto, and H Sasaki, and N Tsuji, and S Akiyama, and D Kobayashi, and T Sato, and N Yamauchi, and Y Niitsu
Tumor necrosis factor-alpha inhibitor associated ulcerative colitis.
March 2007, The American journal of the medical sciences,
N Watanabe, and M Maeda, and T Okamoto, and H Sasaki, and N Tsuji, and S Akiyama, and D Kobayashi, and T Sato, and N Yamauchi, and Y Niitsu
DNA fragmentation and cytotoxicity caused by tumor necrosis factor is enhanced by interferon-gamma.
May 1987, European journal of immunology,
N Watanabe, and M Maeda, and T Okamoto, and H Sasaki, and N Tsuji, and S Akiyama, and D Kobayashi, and T Sato, and N Yamauchi, and Y Niitsu
Tumor necrosis factor alpha in ulcerative colitis and diverticular disease associated colitis.
September 2007, Endocrine, metabolic & immune disorders drug targets,
Copied contents to your clipboard!